These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 8967745)

  • 21. Reduction of fasciculations in patients with amyotrophic lateral sclerosis with the use of gabapentin.
    Romano JG
    Arch Neurol; 1996 Aug; 53(8):716. PubMed ID: 8759976
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapeutic advances: new hope for patients with ALS.
    Forshew DA
    Nurs Spectr (Wash D C); 1998 Dec; 8(25):12-4. PubMed ID: 10542672
    [No Abstract]   [Full Text] [Related]  

  • 23. How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?
    Armon C
    Amyotroph Lateral Scler Other Motor Neuron Disord; 1999 Dec; 1(1):3-14. PubMed ID: 12365066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis.
    McGeer EG; McGeer PL
    BioDrugs; 2005; 19(1):31-7. PubMed ID: 15691215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice.
    Snow RJ; Turnbull J; da Silva S; Jiang F; Tarnopolsky MA
    Neuroscience; 2003; 119(3):661-7. PubMed ID: 12809687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice.
    Nagano S; Fujii Y; Yamamoto T; Taniyama M; Fukada K; Yanagihara T; Sakoda S
    Exp Neurol; 2003 Feb; 179(2):176-80. PubMed ID: 12618124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALS defeats gabapentin: reflections on another failed treatment.
    McDermott MP; Rowland LP
    Neurology; 2001 Apr; 56(7):826-7. PubMed ID: 11294916
    [No Abstract]   [Full Text] [Related]  

  • 28. ALS defeats gabapentin: reflections on another failed treatment.
    Brigell MG; Taylor CP
    Neurology; 2001 Oct; 57(8):1524-5. PubMed ID: 11673613
    [No Abstract]   [Full Text] [Related]  

  • 29. Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases.
    Miller RG
    J Child Neurol; 1999 Mar; 14(3):173-9. PubMed ID: 10190269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells.
    Carrì MT; Ferri A; Battistoni A; Famhy L; Gabbianelli R; Poccia F; Rotilio G
    FEBS Lett; 1997 Sep; 414(2):365-8. PubMed ID: 9315720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyotrophic lateral sclerosis.
    Rowland LP
    Curr Opin Neurol; 1994 Aug; 7(4):310-5. PubMed ID: 7952238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug therapy: On the treatment trail for ALS.
    Scott A
    Nature; 2017 Oct; 550(7676):S120-S121. PubMed ID: 29045376
    [No Abstract]   [Full Text] [Related]  

  • 33. Oxidative stress mediates impairment of muscle function in transgenic mice with elevated level of wild-type Cu/Zn superoxide dismutase.
    Peled-Kamar M; Lotem J; Wirguin I; Weiner L; Hermalin A; Groner Y
    Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3883-7. PubMed ID: 9108073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of riluzole on symptom progression in amyotrophic lateral sclerosis.
    Sojka P; Andersen PM; Forsgren L
    Lancet; 1997 Jan; 349(9046):176-7. PubMed ID: 9111546
    [No Abstract]   [Full Text] [Related]  

  • 35. Amyotrophic lateral sclerosis: from pathological mechanisms to patient care.
    Scarlato G
    J Neurol; 1997 May; 244 Suppl 2():S1-2. PubMed ID: 9178164
    [No Abstract]   [Full Text] [Related]  

  • 36. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn).
    Kennel P; Revah F; Bohme GA; Bejuit R; Gallix P; Stutzmann JM; Imperato A; Pratt J
    J Neurol Sci; 2000 Nov; 180(1-2):55-61. PubMed ID: 11090865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitochondria as possible pharmaceutical targets for the effects of vitamin E and its homologues in oxidative stress-related diseases.
    Majima HJ; Indo HP; Suenaga S; Matsui H; Yen HC; Ozawa T
    Curr Pharm Des; 2011; 17(21):2190-5. PubMed ID: 21774784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increase of flexor reflex latency in patients with amyotrophic lateral sclerosis treated with riluzole.
    Riepe MW; Klappenbach G; Ludolph AC
    J Neurol Neurosurg Psychiatry; 1997 Apr; 62(4):427. PubMed ID: 9120476
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic advances: riluzole for the treatment of motor neurone disease.
    Clark W; Kendall MJ
    J Clin Pharm Ther; 1996 Dec; 21(6):373-6. PubMed ID: 9201563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic trial in amyotrophic lateral sclerosis.
    Dorman JD; Engel WK; Fried DM
    JAMA; 1969 Jul; 209(2):257-8. PubMed ID: 5819233
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.